Emerg Infect DisEmerging Infect. DisEIDEmerging Infectious Diseases1080-60401080-6059Centers for Disease Control and Prevention22608263335815211-121410.3201/eid1806.111214Letters to the EditorLetterESBL-Positive Enterobacteria Isolates in Drinking WaterESBL-Positive Enterobacteria in Drinking WaterDe BoeckHildeMiwandaBertheLunguya-MetilaOctavieMuyembe-TamfumJean-JacquesStobberinghEllenGlupczynskiYouriJacobsJanInstitute of Tropical Medicine, Antwerp, Belgium (H. De Boeck, J. Jacobs);Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo (B. Miwanda, O. Lunguya-Metila, J.J. Muyembe-Tamfum);Maastricht University Medical Center, Maastricht, the Netherlands (E. Stobberingh);Cliniques Universitaires Université Catholique de Louvain de Mont-Godinne, Yvoir, Belgium (Y. Glupczynski)Address for correspondence: Hilde De Boeck, Institute of Tropical Medicine, Nationalestraat 155, Antwerp, Belgium; email: hdeboeck@itg.be6201218610191020Keywords: EnterobacteriaceaeenterobacteriaCTX-M enzymesextended-spectrum β-lactamaseESBLDemocratic Republic of the Congowater qualitysachet packaged waterbacteriadrinking water

To the Editor: Extended-spectrum β-lactamase (ESBL)–producing members of the family Enterobacteriaceae (enterobacteria) are a worldwide problem (1), but little data are available from central Africa (2). In recent years, ESBL-producing Enterobacteriaceae isolates have shifted from the hospital to the community and the environment (1). The aim of this study was to assess the presence of ESBL-producing Enterobacteriaceae isolates in sachet-packaged water bags sold as drinking water in the streets of Kinshasa, the capital of Democratic Republic of the Congo.

In November 2009 and June 2010, a total of 101 sachet-packaged water bags were bought from street vendors in 9 of 24 municipalities (covering residential areas and slums) of the city of Kinshasa. The bags were transported in ice coolers and processed within 4 hours of collection. We filtered 100 mL of each sample through 0.45-µm pore size filters (Sartorius, Goettingen, Germany). The filters were then transferred to an agar plate containing mEndoLES agar (Difco, Franklin Lakes, NJ, USA) and incubated at 35°C for 24 hours.

Growing colonies were subcultured on Kligler iron agar (Oxoid, Cambridge, UK), and gram-negative glucose-fermenting isolates were identified to the species level and assessed for antimicrobial drug susceptibility with Microscan NBC42 panels (Siemens Healthcare Diagnostics Inc., West Sacramento, CA, USA). Isolates labeled by Microscan as ESBL producers were confirmed by the double-disk method, which compared 1 disk containing cefotaxime with 1 disk containing cefotaxime and clavulanic acid and 1 disk containing ceftazidime with 1 disk containing ceftazidime and clavulanic acid (Rosco Diagnostica, Taastrup, Denmark), according to the Clinical and Laboratory Standards Institute guidelines (3). We used Escherichia coli ATCC 25922 and Klebsiella pneumoniae ATCC 700603 as control strains. Detection and identification of ESBL-producing bla genes were carried out by using a commercial multiplex ligation PCR microarray CT 101 (Check-Points Health BV, Wageningen, the Netherlands) (4).

A total of 101 sachet-packaged water bags were purchased at random from different vendors: 88 sealed and branded bags (of 68 different brands) and 13 hand-tied unbranded bags. The precise origin of the water could not be determined because vendors are unlicensed resellers and most producers are not registered. Water bags lacked essential information such as contact addresses, batch number, and production and expiration dates. Because we also observed empty branded sheets of bags for sale on the market, we assumed that many of the branded bags are simply filled with tap water or water from other supplies without any prior treatment. None of the water bags tested for chlorine (36 of 101) contained free chlorine levels >0.1 mg/L. Nearly one third of the water bags were contaminated with Enterobacteriaceae isolates (22/88 branded bags and 9/13 hand-tied bags). The bags were obtained in townships and residential quarters.

Overall, 150 nonduplicate Enterobacteriaceae isolates were recovered. The main species were K. pneumoniae (56.0% of isolates found in 23/101 of water bags) and Enterobacter spp. (30.6%, in 20/101 water bags); Citrobacter spp. accounted for 4.7% of isolates and E. coli for 3.3%. Eight isolates (5.3 %) were confirmed as ESBL producers by antimicrobial drug susceptibility tests, and they were recovered from 2 branded and 2 hand-tied bags. The species, microarray results, and the associated drug resistance are listed in the Table. Five isolates carried blaCTX-M genes belonging to CTX-M1 group, and 3 isolates carried blaSHV variants. No TEM-ESBL genes were detected. On the basis of checkpoint results and previously validated data, we further categorized the SHV G238S mutation as SHV-2-like and the double SHV G238A + SHV E240K mutation as SHV-18 (5).

ESBL-producing <italic>Enterobacteriaceae</italic> recovered from sachet-packaged water bags in Kinshasa, Democratic Republic of the Congo*
Isolate no.SpeciesMicroarray CT101 resultAssociated resistance†
Folate PI
AminoglycosidesFluoroquinolones
44Citrobacter freundiiCTX-M1 groupAMK, GEN, TOBCIP, LEV, MXF, NXNT/S
48Citrobacter freundiiCTX-M1 groupAMK, GEN, TOBCIP, LEV, MXF, NXNT/S
152Enterobacter cloacaeSHV G238S (SHV-2 like)NANAT/S
154Klebsiella pneumoniaeCTX-M1 groupGEN, TOBCIP, MXFT/S
163Citrobacter freundiiCTX-M1 groupNAMXFT/S
165Klebsiella pneumoniaeCTX-M1 groupGEN, TOBNAT/S
170Klebsiella pneumoniaeSHV G238A+E240K(SHV-18)GEN, TOBMXFNA
171Escherichia coliSHV G238A+E240K(SHV-18)GEN, TOBNANA

*ESBL, extended-spectrum β-lactamase; PI, pathway inhibitors; AMK, amikacin; GEN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin; LEV, levofloxacin; MXF, moxifloxacin; NXN, norfloxacin; T/S, trimethoprim/sulfamethoxazole; NA, not applicable.
†Based on interpretive breakpoints as indicated in Clinical and Laboratory Standards Institute guidelines M100-S18, published January 2008.

ESBL-producing Enterobacteriaceae isolates constitute a major public health concern in industrialized and resource-poor settings. Few reports are available from Africa, although hospital-associated ESBL producers have been described in Cameroon and the Central African Republic (6,7). ESBL-producing bacteria have been recovered from different sources in the community, including food and companion animals (8,9), and 1 recent study from India reported that a substantial number of tap water samples were contaminated with carbapenemase blaNDM-1 producing organisms (10).

Kinshasa is the second-largest city in sub-Saharan Africa. In 2008, of its estimated 8.7 million inhabitants, only 46%had access to safe drinking water, and 23% had access to improved sanitation facilities according to the World Bank. Opportunistic pathogens in drinking water and poor sanitary conditions may increase the risk of developing infectious enterocolitis for consumers, especially for those who are immunocompromised. It can eventually lead to chronic intestinal carriage of multidrug-resistant organisms. The presence of ESBL producers in the intestinal flora could also lead to horizontal transfer of drug resistance genes from commensal flora to enteric pathogens. This emergence of ESBL-producing bacteria and further community-associated infections poses a public threat, especially in low-resource countries where surveillance is suboptimal and empiric treatment of invasive infections often includes third-generation cephalosporins.

Suggested citation for this article: De Boeck H, Miwanda B, Lunguya-Metila O, Muyembe-Tamfum J-J, Stobberingh E, Glupczynski Y, et al. ESBL-positive enterobacteria isolates in drinking water [letter]. Emerg Infect Dis [serial on the Internet]. 2012 Jun. http://dx.doi.org/10.3201/eid1806.111214

ReferencesOkeke IN, Laxminarayan R, Bhutta ZA, Duse AG, Jenkins P, O’Brien TF, Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis. 2005;5:48193 10.1016/S1473-3099(05)70189-416048717Vlieghe E, Phoba MF, Tamfun JJ, Jacobs J Antibiotic resistance among bacterial pathogens in central Africa: a review of the published literature between 1955 and 2008. Int J Antimicrob Agents. 2009;34:295303 10.1016/j.ijantimicag.2009.04.01519540725Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: 21st informational supplement. CLSI document M100-S21. Wayne (PA): The Institute; 2011Endimiani A, Hujer AM, Hujer KM, Gatta JA, Schriver AC, Jacobs MR, Evaluation of a commercial microarray system for detection of SHV-, TEM-, CTX-M-, and KPC-type -lactamase genes in gram-negative isolates. J Clin Microbiol. 2010;48:261822 10.1128/JCM.00568-1020504993Bradford PA Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14:93351 10.1128/CMR.14.4.933-951.200111585791Gangoué-Piéboji J, Bedenic B, Koulla-Shiro S, Randegger C, Adiogo D, Ngassam P, Extended-spectrum-β-lactamase-producing Enterobacteriaceae in Yaounde, Cameroon. J Clin Microbiol. 2005;43:32737 10.1128/JCM.43.7.3273-3277.200516000447Frank T, Arlet G, Gautier V, Talarmin A, Bercion R Extended-spectrum β-lactamase-producing Enterobacteriaceae, Central African Republic. Emerg Infect Dis. 2006;12:863 10.3201/eid1205.05095116710958Ewers C, Grobbel M, Stamm I, Kopp PA, Diehl I, Semmler T, Emergence of human pandemic O25:H4-ST131 CTX-M-15 extended-spectrum-β-lactamase–producing Escherichia coli among companion animals. J Antimicrob Chemother. 2010;65:65160 10.1093/jac/dkq00420118165Warren RE, Ensor VM, O’Neill P, Butler V, Taylor J, Nye K, Imported chicken meat as a potential source of quinolone-resistant Escherichia coli producing extended-spectrum β-lactamases in the UK. J Antimicrob Chemother. 2008;61:5048 10.1093/jac/dkm51718222958Walsh TR, Weeks J, Livermore DM, Toleman MA Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis. 2011;11:35562 10.1016/S1473-3099(11)70059-721478057